Natalizumab used in MS treatment blocks the α4β1/VCAM-1 interaction which is required for EAE development [34], thus preventing the migration of leukocytes through the BBB into the inflamed CNS [31,33]. Here, VCAM1 is linked to myeloid sarcoma.